Findings from a recent study showed potential associations between psoriasis, comorbid conditions, and sexual and erectile dysfunction among patients with this skin condition.

FDA Alerts

FDA Alerts
Monday, December 4, 2017
The FDA has expanded the approval of a psoriasis drug to now treat adults with psoriatic arthritis.
FDA Alerts
Monday, October 23, 2017
The FDA has approved extended use of a rheumatoid arthritis drug for the treatment of adult patients with active psoriatic arthritis or active ankylosing spondylitis.
FDA Alerts
Monday, October 16, 2017
The FDA has approved an expanded indication for ustekinumab (Stelara; Janssen) for the treatment of adolescent patients 12 years or older with moderate to severe plaque psoriasis.
FDA Alerts
Tuesday, August 29, 2017
The FDA has approved adalimumab-adbm (Cyltezo), a biosimilar of Humira (adalimumab), for the treatment of multiple inflammatory diseases.

News

News
Wednesday, September 12, 2018
A recent review highlights the most effective, evidence-based complementary and alternative therapies for patients with psoriasis. 
News
Wednesday, September 5, 2018
Results from a recent study, conducted by researchers at the University of Pennsylvania Perelman School of Medicine, highlighted the prevalence of stigmatizing views and myths about psoriasis among a sample of individuals from the US population.
News
Monday, August 20, 2018
Researchers investigated the potential association between psoriasis and clinical markers of cognitive decline using data from the Rotterdam Study.
News
Tuesday, August 14, 2018
Researchers investigated whether a biologic increased the risk for serious infections among patients with psoriasis.

NPF Endorsed Articles

NPF Endorsed Articles
Tuesday, February 27, 2018
The posters presented at The Winter Clinical Dermatology Conference–Hawaii showcased the latest research and management approaches for skin conditions they encounter in clinical practice.
NPF Endorsed Articles
Tuesday, December 22, 2015
Researchers conducted a systematic literature review of 73 published studies to identify factors associated with treatment non-adherence across diseases in rheumatology, gastroenterology and dermatology.   
NPF Endorsed Articles
Monday, December 21, 2015
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy. 
NPF Endorsed Articles
Monday, December 21, 2015
​The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology. 

Research in Review

Research in Review
Tuesday, January 9, 2018
The Research Trainee Symposium brings together the sharpest minds in psoriatic disease research.
Research in Review
Tuesday, December 5, 2017
This case evaluates follicular psoriasis, an uncommon variant manifesting as scaly folliculocentric hyperkeratotic eruptions of the trunk and extremities.
Research in Review
Tuesday, December 5, 2017
This 46-year-old woman had been doing well on adalimumab for the treatment of psoriasis for almost 2 years. She presented with what appeared to be a flare of her psoriasis.
Research in Review
Thursday, November 16, 2017
The condition is characterized by an acute, subacute, or chronic eruption of sterile pustules associated with erythema and inflammation. This patient’s case represents the annular variant characterized by pustules on the periphery of expanding erythematous plaques with central healing, most often localized to the trunk.